Dahua Pharmaceutical has recently received official notification from the Food and Drug Administration of the Philippines (FDA Philippines), confirming its successful completion of the FDA Philippines on-site audit. This achievement fully demonstrates Dahua Pharmaceutical’s outstanding capabilities in quality management system, manufacturing specifications and product quality, laying a solid foundation for further expansion into the Southeast Asian market and the global women’s health sector.

During the on-site audit by FDA Philippines, the audit team conducted a comprehensive review of key areas including quality management, manufacturing facilities and process flows, material management, documentation and records, and personnel training, in strict accordance with Philippine GMP and PIC/S GMP guidelines. All departments of the company worked in close collaboration throughout the audit. With rigorous professionalism and efficient execution, the team actively supported on-site inspections and inquiries, and provided complete, accurate data and documentation. The strong quality awareness, standardized operations and professional competence demonstrated by the company’s management and frontline staff were highly recognized by the audit team. Following the submission of the corrective action report, the FDA Philippines completed a rigorous three-month review and finally granted a pass result for this audit. This outcome not only validates the effectiveness and compliance of Dahua Pharmaceutical’s quality management system, but also serves as solid recognition of the company’s long-standing commitment to the philosophy of “Quality First” and continuous optimization of manufacturing and management systems.

Going forward, Dahua Pharmaceutical will continue to comply with relevant international standards and guidelines, steadily improve quality management and manufacturing compliance, and deliver safer, higher-quality pharmaceutical products and healthcare services to women worldwide.